Latent tuberculosis prevalence, diagnosis and treatment in Multiple Sclerosis as a strategy for reducing infection reactivation during immunosuppressant therapy
- 15 April 2024
- journal article
- research article
- Published by Elsevier in Multiple Sclerosis and Related Disorders
- Vol. 86, 105632
Abstract
No abstract availableKeywords
This publication has 10 references indexed in Scilit:
- Latin American consensus recommendations on the risk of infections in people with multiple sclerosis treated with disease modifying drugsMultiple Sclerosis and Related Disorders, 2023
- Latent Tuberculosis InfectionNew England Journal of Medicine, 2021
- Latent tuberculosis infection reactivation in patients with multiple sclerosis in use of disease-modifying therapies: A systematic reviewMultiple Sclerosis and Related Disorders, 2021
- Diagnosis and Treatment of Multiple SclerosisJAMA, 2021
- The risk of infection in patients with multiple sclerosis treated with disease-modifying therapies: A Delphi consensus statementMultiple Sclerosis Journal, 2020
- Prevalence of Latent Tuberculosis in the Multiple Sclerosis Clinic and Effect of Multiple Sclerosis Treatment on Tuberculosis TestingInternational Journal of MS Care, 2020
- Infectious Complications of Multiple Sclerosis Therapies: Implications for Screening, Prophylaxis, and ManagementOpen Forum Infectious Diseases, 2018
- Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteriaThe Lancet Neurology, 2018
- Infectious risk stratification in multiple sclerosis patients receiving immunotherapyAnnals of Clinical and Translational Neurology, 2017
- How do we manage and treat a patient with multiple sclerosis at risk of tuberculosis?Expert Review of Neurotherapeutics, 2014